MAIA Biotechnology

IN THE PRESS

FDA

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

November 10, 2023

·

8 min read

BioMidwest

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

November 7, 2023

·

9 min read

BioMidwest

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

October 30, 2023

·

6 min read

Drug Development

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

October 24, 2023

·

6 min read

BioMidwest

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

October 19, 2023

·

6 min read

BioMidwest

MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023

October 17, 2023

·

5 min read

BioMidwest

MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

October 12, 2023

·

5 min read

Drug Development

MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients

October 10, 2023

·

6 min read

BioMidwest

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

October 10, 2023

·

5 min read

Drug Development

MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

October 3, 2023

·

6 min read

JOBS